Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma | Zendy

James Nguyen | Zendy; Naoko Takebe | Zendy; Shivaani Kummar | Zendy; Albiruni R. Abdul Razak | Zendy; Sant P. Chawla | Zendy; Suzanne George | Zendy; Shreyaskumar Patel | Zendy; Mary Louise Keohan | Zendy; Sujana Movva | Zendy; Geraldine O’Sullivan Coyne | Zendy; Khanh Do | Zendy; Lamin Juwara | Zendy; Brooke Augustine | Zendy; Seth M. Steinberg | Zendy; Laura Kuhlmann | Zendy; S. Percy Ivy | Zendy; James H. Doroshow | Zendy; Alice Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Author(s) -

James Nguyen,

Naoko Takebe,

Shivaani Kummar,

Albiruni R. Abdul Razak,

Sant P. Chawla,

Suzanne George,

Shreyaskumar Patel,

Mary Louise Keohan,

Sujana Movva,

Geraldine O’Sullivan Coyne,

Khanh Do,

Lamin Juwara,

Brooke Augustine,

Seth M. Steinberg,

Laura Kuhlmann,

S. Percy Ivy,

James H. Doroshow,

Alice Chen

Publication year - 2022

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-22-2145

Subject(s) - medicine , sunitinib , tolerability , clinical endpoint , response evaluation criteria in solid tumors , oncology , randomized controlled trial , progressive disease , soft tissue sarcoma , phases of clinical research , tyrosine kinase inhibitor , surgery , clinical trial , gastroenterology , adverse effect , cancer , chemotherapy , soft tissue

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research